quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·27d
PRRelease
Eli Lilly and Company logo

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

LLY· Eli Lilly and Company
Health Care
Original source

Companies

  • LLY
    Eli Lilly and Company
    Health Care

Recent analyst ratings

  • Mar 17UpdateHSBC Securities$850.00
  • Feb 25UpdateRBC Capital Mkts$1,250
  • Feb 20UpdateBarclays$1,350
  • Jan 7UpdateUBS$1,250
  • Dec 16UpdateDaiwa Securities$1,230
  • Dec 15UpdateGoldman$1,145

Related

  • PR17h
    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
  • INSIDER2d
    SEC Form 4 filed by Sulzberger Gabrielle
  • INSIDER2d
    SEC Form 4 filed by Luciano Juan R
  • INSIDER2d
    SEC Form 4 filed by Fyrwald J Erik
  • INSIDER2d
    SEC Form 4 filed by Alvarez Ralph
  • PR3d
    Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
  • PR7d
    Lilly confirms date and conference call for first-quarter 2026 financial results announcement
  • PR7d
    ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022